<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="70574"><DrugName>AdCh3NSmut1 + MVA-NSmut (HCV), ReiThera/University of Oxford</DrugName><DrugSynonyms><Name><Value>MVA vaccine (hepatitis C virus), Okairos</Value></Name><Name><Value>AdCh3NSmut/MVA-NSmut prime-boost vaccine (HCV), Okairos</Value></Name><Name><Value>MVA vaccine (HCV), Okairos</Value></Name><Name><Value>AdCh3NSmu1/MVA-NSmut vaccine (HCV), Okairos</Value></Name><Name><Value>MVA vaccine (HCV), ReiThera</Value></Name><Name><Value>MVA vaccine (hepatitis C virus), ReiThera</Value></Name><Name><Value>AdCh3NSmut1 + MVA-NSmut (HCV), ReiThera/University of Oxford</Value></Name></DrugSynonyms><CompanyOriginator id="1035490">ReiThera Srl</CompanyOriginator><CompaniesSecondary><Company id="1035490">ReiThera Srl</Company><Company id="22182">University of Oxford</Company></CompaniesSecondary><CrossReferences><SourceEntity id="70574" type="Drug"><TargetEntity id="732519" type="siDrug">HCV-003</TargetEntity></SourceEntity><SourceEntity id="1035490" type="Company"><TargetEntity id="5036178929" type="organizationId">Reithera SRL</TargetEntity></SourceEntity><SourceEntity id="22182" type="Company"><TargetEntity id="5000698033" type="organizationId">University of Oxford</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="12370">Recombinant viral vector vaccine</Action><Action id="12378">Prophylactic vaccine</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="62">Virus recombinant</Technology><Technology id="651">Intramuscular formulation</Technology></Technologies><LastModificationDate>2019-06-03T11:37:17.000Z</LastModificationDate><ChangeDateLast>2019-06-05T00:00:00.000Z</ChangeDateLast><AddedDate>2011-03-22T16:33:49.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1035490" linkType="Company"&gt;ReiThera&lt;/ulink&gt; (formerly Okairos), a subsidiary of &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt;, and &lt;ulink linkID="22182" linkType="Company"&gt;University of Oxford&lt;/ulink&gt; were developing a heterologous, prophylactic, prime-boost vaccine consisting of  the adenoviral vector AdCh3NSmut and the modified Vaccinia Ankara MVA-NSmut, both of which express the non-structural mutant  HCV protein NSmut, for the potential im prevention of HCV infection [&lt;ulink linkID="1178463" linkType="Reference"&gt;1178463&lt;/ulink&gt;], [&lt;ulink linkID="1178471" linkType="Reference"&gt;1178471&lt;/ulink&gt;], [&lt;ulink linkID="1430235" linkType="Reference"&gt;1430235&lt;/ulink&gt;], [&lt;ulink linkID="1634158" linkType="Reference"&gt;1634158&lt;/ulink&gt;], [&lt;ulink linkID="2157829" linkType="Reference"&gt;2157829&lt;/ulink&gt;]. In March 2012, a  phase I/II trial was initiated [&lt;ulink linkID="2157829" linkType="Reference"&gt;2157829&lt;/ulink&gt;]. In May 2019, negative data were reported and development was presumably discontinued [&lt;ulink linkID="2157457" linkType="Reference"&gt;2157457&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company is also developing &lt;ulink linkID="58627" linkType="Drug"&gt;PerCvax&lt;/ulink&gt; and &lt;ulink linkID="58628" linkType="Drug"&gt;TerCvax&lt;/ulink&gt;, vaccines for HCV prevention and treatment, respectively, which are  based on adenovirus vectors expressing NSmut. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2012, an interventional,  randomized, parallel assignment, staged phase I/II trial (&lt;ulink linkID="81039" linkType="Protocol"&gt;NCT01436357&lt;/ulink&gt;; 10-0069) was initiated in the US  to evaluate the safety, efficacy and immunogenicity of AdCh3NSmut1 and MVA-NSmut in hepatitis C virus (HCV) uninfected male and female injection drug users (IDU) aged 18 to 45 years (n = 548). In May 2018, the trial was completed [&lt;ulink linkID="2157829" linkType="Reference"&gt;2157829&lt;/ulink&gt;]. In May 2019, negative data were reported. Data  demonstrated that the vaccine was not found to be effective at preventing chronic hepatitis C virus (HCV) infection in adults as compared to placebo [&lt;ulink linkID="2157457" linkType="Reference"&gt;2157457&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2015, a single group assigned, phase I trial (&lt;ulink linkID="242215" linkType="Protocol"&gt;NCT02568332&lt;/ulink&gt;; PEACHI-02) to assess the safety and immunogenicity of prime boost immunisations with AdCh3NSmut and MVA-NSmut in seropositive HCV-uninfected adults (expected n = 20) on antiretroviral therapyÂ was initiated in Ireland and Switzerland. At that time, the trial was expected to be completed in October 2017 [&lt;ulink linkID="1936324" linkType="Reference"&gt;1936324&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, an open label, non-randomized, parallel, phase I trial (&lt;ulink linkID="221761" linkType="Protocol"&gt;NCT02362217&lt;/ulink&gt;; PEACHI-04), to assess the safety of AdCh3NSmut1/MVA-NSmut and HIV vaccines&lt;ulink linkID="70762" linkType="Drug"&gt; AdCh3NSmutI/ChAdV63.HIVconsv&lt;/ulink&gt; when administered separately or in combination to healthy volunteers  (expected n = 32) in UK. At that time, the trial was expected to be completed in October 2016 [&lt;ulink linkID="1634158" linkType="Reference"&gt;1634158&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2011, a phase I study (&lt;ulink linkID="75080" linkType="Protocol"&gt;NCT01296451&lt;/ulink&gt;, HCV003) was initiated in the UK, in which 23 HCV patients and healthy volunteers would receive  either MVA-NSmut alone or AdCh3NSmut followed by MVA-NSmut. The trial would assess adverse events and T-cell immune responses. At taht time, the trial was expected to complete in May 2014. In May 2013, the trial was still in recruitment [&lt;ulink linkID="1178463" linkType="Reference"&gt;1178463&lt;/ulink&gt;]. In April 2016, data were presented at the 51st EASL International Liver Congress in Barcelona, Spain. There were no observed serious adverse events or suspected unexpected serious adverse reactions. In the short interval group (Ad doses on Weeks 0 and 16, and MVA given on Weeks 8 and 24) there was an attenuated response to reboosting. In a long interval group (Ad doses on Weeks 0 and 61 and MVA on Weeks 8 and 69) there was a robust T-cell response. A third group in which reboosting was done with MVA only also showed a robust T-cell response [&lt;ulink linkID="1751956" linkType="Reference"&gt;1751956&lt;/ulink&gt;], [&lt;ulink linkID="1751984" linkType="Reference"&gt;1751984&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1035490">ReiThera Srl</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035490">ReiThera Srl</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035490">ReiThera Srl</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035490">ReiThera Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22182">University of Oxford</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22182">University of Oxford</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-05-29T00:00:00.000Z</StatusDate><Source id="2157457" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1035490">ReiThera Srl</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-09T00:00:00.000Z</StatusDate><Source id="1178463" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035490">ReiThera Srl</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-30T00:00:00.000Z</StatusDate><Source id="1936324" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035490">ReiThera Srl</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-06T00:00:00.000Z</StatusDate><Source id="2157829" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035490">ReiThera Srl</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-30T00:00:00.000Z</StatusDate><Source id="1936324" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22182">University of Oxford</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-30T00:00:00.000Z</StatusDate><Source id="1936324" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22182">University of Oxford</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-30T00:00:00.000Z</StatusDate><Source id="1936324" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-02-11T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035490">ReiThera Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-09T00:00:00.000Z</StatusDate><Source id="1178463" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2157457" linkType="reference" linkID="2157457"&gt;2157457&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="22182">University of Oxford</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="153150" title="University of Oxford to develop Okairos' AdCh3NSmut/MVA-NSmut prime-boost HCV vaccine   "></Deal></Deals><PatentFamilies><PatentFamily id="3542217" number="WO-2017025782" title="Improved poxviral vaccines"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>